Limited β₂-adrenoceptor haplotypes display different agonist mediated airway responses in asthmatics
Anneke van Veen¹, Eddy A Wierenga², Robert Westland², Frank R Weller¹, Guus AM Hart³, Henk M Jansen¹ and René E Jonkers*¹

Address: ¹Department of Pulmonology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands, ²Department of Cell Biology and Histology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands and ³Department of Epidemiology and Biostatistics, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands

Email: Anneke van Veen - a.vanveen@amc.uva.nl; Eddy A Wierenga - e.a.wierenga@amc.uva.nl; Robert Westland - r.westland@amc.uva.nl; Frank R Weller - fweller@heideheuvel.nl; Guus AM Hart - a.a.hart@amc.uva.nl; Henk M Jansen - h.m.jansen@amc.uva.nl; René E Jonkers* - r.e.jonkers@amc.uva.nl

* Corresponding author

Abstract

Background: In vitro and some in vivo studies suggested that genetic haplotypes may have an impact on β₂-agonist mediated airway responses in asthmatics. Due to strong linkage disequilibrium the single nucleotide polymorphisms (SNPs) in the β₂-adrenoceptor gene result in only a limited number of haplotypes. We intended to evaluate the impact of β₂-adrenoceptor haplotypes on β₂-agonist mediated airway responses and the development of tolerance in mild to moderate asthmatics.

Methods: Patients were genotyped for the part of the β₂-adrenoceptor gene with a known bearing on receptor function and regulation. Cumulative dose response curves of fenoterol versus PD₂₀ methacholine and FEV₁ were constructed after 2 week treatment periods with either terbutaline or placebo in a double blind, randomised and cross-over design. Analysis of the dose response curves was based on a repeated measurement analysis of covariance.

Results: In our study population comprising 45 asthmatic patients, we found three limited allelic haplotypes, resulting in six different genotypes. Our data support the existence of differences between these six genotypes both in the shape of the dose response relationship of the β₂-adrenoceptor agonist fenoterol as well as in the propensity to develop tolerance for these effects by pre-treatment with terbutaline. However, this could only be substantiated for the endpoint PD₂₀ methacholine.

Conclusion: Between β₂-adrenoceptor genotypes differences exist both in baseline β₂-agonist induced airway responses as well as in the propensity to develop tolerance during maintenance β₂-agonist therapy. The net differences after two weeks of therapy are, however, of magnitudes that are unlikely to be of clinical significance.
Background

Over the past decade an increasing number of single nucleotide polymorphisms (SNPs) in the β2-adrenoceptor (β2-AR) gene have been identified. Initially the focus of research was on two highly prevalent non-synonymous SNPs in the coding region of the gene that both result in an amino acid substitution in the extra-cellular part of the receptor protein: position 16 Arg→Gly and position 27 Gln→Glu. In vitro these amino acid changes appeared to alter the susceptibility to receptor downregulation by exposure to β2-agonists [1,2]. These observations fuelled a number of clinical and in vitro/ex vivo studies yielding inconsistent and sometimes conflicting results. Arg-16 was found to be associated with a greater acute bronchodilator response to a β2-AR agonist [3,4], but also with loss of asthma control in some studies [5,6], but not in all [7]. In an ex vivo study using human peripheral blood lymphocytes no impact of either polymorphism could be substantiated on baseline receptor expression or responsiveness[8].

It is generally assumed that the in vivo consequence of the downregulation of β2-ARs is tolerance towards the airway smooth muscle mediated effects of β2 agonists. This tolerance has generally been difficult to show for the bronchodilator effects of β2-AR agonists, but is more pronounced and potentially clinically relevant for their bronchoprotective effects [9]. The relationship between the polymorphic amino acids 16 and 27 and the susceptibility to bronchodilator tolerance was the subject of two clinical studies [10,11], but in only one of these such an association could be substantiated [10]. Tolerance development towards the bronchoprotective effects of β2-agonists was the subject of two prospective clinical studies, which did not find differences between amino acid 16 genotypes [12,13]. Results of in vitro studies using either human mast cells or airway smooth muscle cells did not aid in settling the issue [14,15].

More recently additional SNPs in the non-coding regulatory part of the β2-AR gene were described, some of which affect receptor expression and regulation in vitro [16-18]. These SNPs are in strong linkage disequilibrium with those coding for amino acid 27 in the β2-AR protein, which results in only a very limited variation in extended allelic haplotypes [16,18,19]. In vitro studies initially focused on the SNPs in the 5’ flanking region of the receptor coding block in isolation. Analysis of the relative promoter activities of serially truncated fragments of the 5’ flanking region suggested that the regulatory activity of the β2-AR gene is largely concentrated in the region of 550 base pair 5’ to the coding block. In particular, deletion of the region containing the -367 SNP strongly reduced transcription. In a comparative assay, alleles containing the -367 T→C mutation were shown to result in a lower transcription rate (~17%) [18]. Recently, we were able to confirm this finding and showed that this was associated with the decreased binding of an as yet unidentified transcription factor [20].

The intronless coding region of the β2-AR protein is preceded by a small open reading frame encoding a 19 amino acid peptide, the β2-AR upstream peptide (BUP), which inhibits β2-AR mRNA translation [17]. The -47 C/T SNP leads to a Cys → Arg substitution at position 19 of the BUP. Transfection experiments with constructs containing either variant of this SNP showed that Cys19 resulted in an increase in receptor protein expression through an effect on mRNA translation [16]. However, when the BUP SNP was studied in the context of a validated haplotype, the BUP Cys19 allele was associated with decreased receptor protein and mRNA expression, which appeared to be associated with a decreased bronchodilator response to an inhaled β2-agonist in a cross-sectional study in a cohort of asthmatics [19]. On the basis of this later observation these authors advocated studying the biological phenotypic consequences of the β2-AR SNPs only within the context of validated haplotypes. In fact, our study extends on this study. For our functional analyses we limited the haplotypes to the SNPs in the 5’region of the gene, of which an influence on transcription and regulation may be expected, combined with the two far most prevalent non-synonymous SNPs in the receptor protein coding block at +46 and +79.

Our primary aim was to study the impact of different combinations of allelic haplotypes on tolerance to β2-agonist induced bronchoprotection. To this end, we conducted a double blind cross-over study of two-week treatment periods with either the short-acting β2-agonist terbutaline or a matching placebo. Cumulative dose response curves of the full β2-AR agonist fenoterol versus PD20 methacholine were used as the main physiologic endpoint.

We found differences between six distinct β2-AR allelic genotypes in the shape of the dose response relationship and in the propensity to develop tolerance for these effects. These differences are statistically significant and functionally relevant only for bronchoprotection when compared to bronchodilation in terms of recovery from metacholine induced bronchoconstriction. The magnitudes of the net differences are, however, unlikely to be of clinical significance

Methods

Patients

Recruitment of patients with mild to moderate asthma and inclusion criteria have been described in detail elsewhere [21]. According to current guidelines all patients used inhaled corticosteroids, of which the dose was kept...
stable from at least 8 weeks prior to inclusion until the end of the study. If inclusion criteria were met, a blood sample was drawn for isolation of DNA. All subjects gave written informed consent to participate in the study that was approved by the Medical Ethics Committee of the Academic Medical Centre in Amsterdam.

**Design**

The study had a randomized, placebo-controlled, double-blind, cross-over design. Two treatment periods of two weeks were preceded and separated by wash-out periods of two weeks, during which all \( \beta_2 \)-agonists were discontinued and only ipratropium bromide pressurized metered dose inhaler (pMDI) was allowed for symptom relief. During the treatment periods a dry powder inhaler (Turbuhaler\textsuperscript{*}, Astra-Zeneca, Zoetermeer, the Netherlands) containing either 500 \( \mu \)g of terbutaline per inhalation or placebo was used four times daily. The subjects attended to the laboratory 24 hours after the last dose of study medication and after ipratropium had been withheld for at least 8 hours. After baseline FEV\textsubscript{1} and PD\textsubscript{20} methacholine had been determined, subjects inhaled 200 \( \mu \)g of fenoterol pMDI from an aerochamber as the first of a series of 4 doubling doses, resulting in cumulative doses of 200, 600, 1400, and 3000 \( \mu \)g respectively. One hour after each dose of fenoterol a PD\textsubscript{20} methacholine was determined, immediately after which the next dose of fenoterol was inhaled. Lung function measurements and methacholine provocation tests were done as described previously [21].

**Assessment of extended \( \beta_2 \)-adrenoceptor genotypes**

Genomic DNA was extracted from peripheral blood mononuclear cells. Using allele-specific primers distinguishing between the -367T- and -367C-alleles, DNA was amplified by PCR, applying standard conditions. The fragment between nucleotides -367 and + 377 was amplified using sense primers 7 or 8 (Table 1) and anti-sense primer 2, and the fragment between -367 and -1081 was amplified with anti-sense primers 214 or 215 and sense primer 216. The PCR products were separated by agarose gel electrophoresis and isolated from the gel. Using the same -367 haplotype-specific primer sets, the sequence of the PCR products was determined by automatic sequencing. In case of -367 homozygous patients within the cohort studied, heterozygous polymorphisms downstream or upstream were limited to the +46 SNP, thus still allowing for the assessment of the full haplotypes.

**Statistical analysis**

Patients were divided into subgroups according to their established allelic genotypes, based on combinations of the three found limited allelic haplotypes I, II, and III. FEV\textsubscript{1} values are presented as % predicted, methacholine provocation test results as (geometric mean) PD\textsubscript{20} (\( \mu \)g). Baseline FEV\textsubscript{1} and PD\textsubscript{20} are those measured after a two week wash out period followed by a two week placebo treatment period and before administration of the first dose of fenoterol.

Because of the markedly skewed distribution of PD\textsubscript{20} values, these were logarithmically transformed prior to analysis. Analysis of the dose response curves was based on a repeated measurement analysis of covariance with log(PD\textsubscript{20}) or FEV\textsubscript{1} (% predicted) as dependent variable, fenoterol dose, treatment (terbutaline vs. placebo), combined allelic genotype and period as factors, baseline log(PD\textsubscript{20}) or FEV\textsubscript{1} respectively as a covariate and patient as subject within whom repeated measurements may be correlated. An unstructured covariance matrix was used, implying possible differences in SD’s at the 8 different fenoterol doses by treatment combinations, as well as varying within-patient correlations between these 8 measurements (heteroscedastic). In the model, all possible interactions were allowed between the three factors fenoterol dose, treatment (terbutaline vs. placebo) and combined allelic genotype. P-values were calculated from a Wald-based F-test with denominator degrees of freedom from the ‘within-between’ method. The analysis comprised a total of 8 global model and 6 within-genotype comparisons and associated P-values. Standard, P-values were not adjusted for multiple comparisons.

For PD\textsubscript{20} results (means and means ± SE’s) from the analyses were back-transformed to the normal scale. The statistical package SAS 8.2 was used for the calculations.

---

**Table 1: Primers used for allele-specific PCR amplification and sequencing.**

| Primer | Fragment | direction | Sequence |
|--------|----------|-----------|----------|
| 2      | +396/+377| Antisense | 5’-gtagcgatcactcgatc-3’ |
| 7      | -387/-367| Sense     | 5’-ggcgcaggccgcgagc-3’ |
| 8      | -387/-367| Sense     | 5’-ggcgcaggccgcgagc-3’ |
| 214    | -1081/-1061| Antisense | 5’-ctgcaatctcagggagc-3’ |
| 215    | -349/-367| Antisense | 5’-ctcgccctccttcctcga-3’ |
| 216    | -349/-367| Antisense | 5’-ctgccctccttcctcgg-3’ |
Results

Patient characteristics

A total of 50 patients were enrolled of whom 45 (11 male/34 female), with a mean FEV₁ of 84.6 % predicted, and a geometric mean PD₂₀ methacholine of 163 µg completed the study. Two patients discontinued the study because of side effects of the study medication (palpitations and tremor). Two patients were excluded because of not allowed use of β₂-AR agonist as was one female patient that turned out to be pregnant during the course of the study.

The cohort of the 45 patients that completed the study comprised 5 haplotypes within the part of the β₂-AR gene between nucleotides -1023 and + 79 (table 2), two of which occurred only single, one of which (Ic) has not been described previously. As described by others, linkage disequilibrium was found between nucleotides -367 T/C, -47 T/C (coding for Arg/Cys19 of the 5' leader peptide (5'LP)), -20 T/C and + 46 A/G (coding for Glu/Gln27 of the β₂AR protein). This resulted in the presence within the cohort of only 3 limited haplotypes with considerably differences in (relative) frequencies (table 3). Baseline patient characteristics of these combined limited allelic haplotypes (or allelic genotypes) (table 3) as well as those of the subgroups based upon the amino acid 16 and 27 polymorphisms displayed no statistically significant differences.

Table 2: Localization of SNPs and delineation of haplotypes of the β2-AR gene in the cohort. The limited haplotypes correspond to the SNPs in boldface. Haplotypes between brackets correspond to those of Drysdale et al.

| Nucleotide: | -1023 | -654 | -468 | -367 | -47 | -20 | 46 | 79 |
|------------|-------|------|------|------|-----|-----|-----|-----|
| Alleles    | G/A   | G/A  | C/G  | T/C  | T/C | T/C | G/A | C/G |
| Limited Haplotype |       |      |      |      |     |     |     |     |
| III Arg19Gly16Glu27 (2) | A | G | G | C | C | C | G | G |
| la Cys19Arg16Gln27 (4) | G | A | C | T | T | T | A | C |
| II Cys19 Gly16Gln27 (6) | G | A | C | T | T | T | G | C |
| lb Cys19Arg16Gln27 (1) | A | G | C | T | T | T | A | C |
| lc Cys19Arg16Gln27 (x) | G | G | G | T | T | T | A | C |

Table 3: Frequencies and patient characteristics of the subgroups formed by the combined limited allelic haplotypes. Baseline FEV₁ and PD₂₀ were measured after a two week washout period followed by a two week placebo treatment period, before administration of the first dose of fenoterol.

| Genotype | Frequency | Baseline FEV₁ (% of predicted), mean (range) | Baseline PD₂₀, geometric, mean (range) | Inhalation steroid dose, mean (range) |
|----------|-----------|---------------------------------------------|----------------------------------------|----------------------------------|
| I/III    | 14 (31%)  | 85 (59 – 107)                                | 141 (24 – 761)                         | 470 (200 – 1200)                  |
| III/III  | 10 (22%)  | 86 (54 – 104)                                | 313 (92 – 1240)                        | 440 (200 – 1000)                  |
| II/III   | 5 (11%)   | 81 (72 – 99)                                 | 110 (20 – 371)                         | 380 (200 – 500)                   |
| I/II     | 10 (22%)  | 85 (60 – 101)                                | 176 (29 – 672)                         | 530 (200 – 1000)                  |
| I/III    | 4 (9%)    | 82 (70 – 94)                                 | 74 (30 – 157)                          | 500 (400 – 800)                   |
| II/II    | 2 (4%)    | 88 (82 – 93)                                 | 148 (33 – 668)                         | 500 (200 – 800)                   |

Influence of the genetic polymorphisms and of terbutaline pre-treatment on the β₂-agonist mediated effects on asthmatic airways

A. Bronchoprotection

Baseline PD₂₀ methacholine values after placebo pre-treatment as compared to terbutaline pre-treatment were of a similar magnitude and not statistically different. Figure 1 shows the back-transformed means and SE's for PD₂₀ methacholine, estimated from the model described above and corrected for baseline. There was no evidence that the shape differences on the log-scale between the dose-response curves for the two treatments vary between the allelic genotypes (interaction: pre-treatment * fenoterol dose * genotype, P = 0.23). However, there was evidence that the difference in PD₂₀ between the two treatments, averaged over fenoterol dose, is related to allelic genotype (interaction: pre-treatment * genotype, P = 0.0029) and also that the shape of the dose-response curve, averaged over both treatments, varies between the allelic genotypes (interaction: fenoterol dose * genotype, P = 0.0011). No firm evidence was found that the relative difference in PD₂₀ between terbutaline pre-treatment and placebo pre-treatment varies over the fenoterol dose (interaction: pre-treatment * fenoterol dose, P = 0.071), giving additional support for the averaging over fenoterol dose. Averaged over fenoterol dose and genotype, terbutaline pre-treatment reduced PD₂₀ compared to placebo pre-treatment (P = 0.0026). Terbutaline pre-treatment
reduced PD_{20} by 53% (95% CI: 31–68%, P = 0.0004) on average for I/III patients and by 66% (95% CI: 35–82%, P = 0.0019) for II/III patients (Table 4). I/II patients showed a comparable, but non-significant reduction. For the other genetic groups, reductions are lower, if existing at all (Table 4). Adjustment for multiple comparisons – by for instance the Bonferroni correction – would not change these conclusions qualitatively. After application of a most conservative approach, i.e. by multiplying the uncorrected P-values by 14, the highest significant P-value of 0.0029 for the pre-treatment * genotype interaction would still remain below the level of 0.05, namely 0.041. For the within-genotype significant P-values for genotypes I/III and II/III the values would become 0.0056 and 0.0154 respectively.

B. Recovery by fenoterol of methacholine induced bronchoconstriction

Figure 2 shows means and SE's for FEV_{1} measured one hour after fenoterol inhaled directly after the previous PD_{20} measurement, as estimated from the model and corrected for baseline. There was no evidence that the shape differences between the dose-response curves for the two treatments vary between the allelic genotypes (interaction: pre-treatment * fenoterol dose * genotype, P = 0.48). Neither was there evidence that the difference in FEV_{1} between terbutaline pre-treatment and placebo pre-treat-
ment varied over the fenoterol dose (interaction: pre-treatment * fenoterol dose, P = 0.46), nor that the difference in FEV$_1$ between the two treatments, averaged over fenoterol dose, is related to allelic genotype (interaction: pre-treatment * genotype, P = 0.29, see table 5). There was some evidence that averaged over both treatments, varies between the allelic genotypes (interaction: fenoterol dose * genotype, P = 0.68) percent points. Only for genotype I/I this decrease reached statistical significance (see table 5). Adjustment for multiple comparisons, by for instance the Bonferroni correction, reduced all these findings to non-significance.

**Discussion**

This is the first study finding differences between β$_2$-AR genotypes in the shape of the dose response relationship of β$_2$-AR mediated airway effects in asthmatics in vivo. Our data analysis, however, does not allow a further distinction in differences with respect to specific characteristics of the dose response curves, such as the maximum effect at infinite drug dose (Emax) or the dose at which 50% of this maximum effect is obtained (ED50). We found no evidence for an interaction between treatment and genotype influencing the shape of the dose response curve of PD$_{20}$ methacholine. Neither was there evidence that the relative differences in PD$_{20}$ after terbutaline pre-treatment and placebo pre-treatment vary over the fenoterol dose, as illustrated in figure 5. These latter two findings suggest that, at least with respect to protection against methacholine induced bronchoconstriction, there is a genotype-specific way by which binding of a β$_2$-AR agonist to its receptor translates into a clinical response as well as a genotype specific but β$_2$-agonist-dose-independent impact of tolerance development on this response. The latter is illustrated by the parallel course of the two dose responses curves within the different genotypes on semilogscale (figure 5).

The functional differences we observed between the allelic genotypes cannot be explained by the known functional consequences of individual SNPs or of haplotypes as delineated in vitro. Moreover, the functional phenotype of heterozygotic genotypes does not appear to fit in with that of the homozygotic variants. For instance, in our study genotypes I/I and III/III appear to be resistant to downregulation, while genotype I/III showed a significant degree of downregulation for bronchoprotection by fenoterol. Patients heterozygous on position 19 of the BUP and position 27 of the β$_2$-AR, genotypes I/III and II/III, appeared to be most affected by desensitization, with reductions in PD$_{20}$ of 53 and 66%, respectively. This is in line with a study that found more desensitization in human airway smooth muscle cells derived from individuals who were heterozygous on position 27 [15]. Our findings illustrate why previous studies focusing on single SNPs in the receptor protein coding block may have yielded negative or even contradictory results. For example, the sub-group of Gly-16 homozygotes consists of three genotypes, III/III, II/III and II/II, with apparently different baseline β$_2$-AR agonist mediated responses and propensities to develop downregulation. This implicates that the results of functional studies based solely on variation in amino acid 16 will depend upon the distribution of genotypes within the subgroup of Gly-16 homozygotes.

The absence of a clear-cut relationship between genotypes and functional phenotypes suggests the influence of other yet unidentified co-factors. The identification of one such factor may come from recent findings in mouse models suggesting the existence of "cross-talk" in airway smooth muscle between the β$_2$-AR system and G$_q$-phospholipase C coupled receptors responding to contractile agonists such as methacholine [22]. The findings in this animal model of an increase in cholinergic sensitivity in the absence of chronic β$_2$-AR stimulation and vice versa, fit in with our observation of a combination of apparent resistance to downregulation with respect to bronchoprotection (figure 1 and table 4) combined with the numerative

### Table 4: The reduction in bronchoprotection by fenoterol after terbutaline pre treatment as compared to placebo pre treatment. The response was averaged over fenoterol dose 200–3000 µg. A 50% reduction corresponds to one double dose reduction of PD$_{20}$ methacholine. Negative numbers indicate an increase in response.

| Allelic genotype | Median | 95% CI | P-value |
|------------------|--------|--------|---------|
| I/III            | 53%    | 31%    | 68%     | 0.0004  |
| III/III          | 22%    | -24%   | 50%     | 0.30    |
| II/III           | 66%    | 35%    | 82%     | 0.0019  |
| I/I              | -51%   | -139%  | 4%      | 0.078   |
| I/II             | 50%    | -2%    | 76%     | 0.059   |
| II/II            | 25%    | -106%  | 73%     | 0.58    |
(and borderline significant) largest degree of loss of bronchodilation (figure 2 and table 5) within genotype I/I. Since subjects of this genotype are homozygous Arg16/Arg16, our data in this genotype agree with those of Israel et al [6] who found an increased response to anti-cholinergic therapy in patients of this genotype when they were off β2-agonist therapy, in combination with no improvement in lung function when they were on β2-agonist therapy.

Some potential limitations of our study need to be discussed. Our active treatment arm consisted of the short acting β2-agonist terbutaline, where long-acting β2-agonists are nowadays the standard for maintenance bronchodilator therapy in asthma. What matters, however, is whether the degree of "receptor stimulation" we obtained is representative for the usual situation in maintenance therapy. In this respect it is relevant that the dose of terbutaline we employed is generally considered to be about therapeutically equivalent to the standard doses of the two long-acting β2-agonists formoterol and salmeterol. Furthermore, in a direct comparison 500 µg of terbutaline induced a degree of bronchoprotective subsensitivity of a same order of magnitude as the usually employed doses of formoterol [23]. Using either formoterol or salmeterol would also have limited the extent to which findings with either of this drugs can be generalized in view of their differences in intrinsic efficacy. Relevant in this respect may be that in vitro [24] the intrinsic efficacy of terbutaline appears to be in between those of salmeterol and formoterol. Next, the "test drug" we employed for the functional
studies was fenoterol which is a full \( \beta_2 \)-AR agonist, like formoterol, but unlike salbutamol, salmeterol and also terbutaline that are partial agonists \textit{in vitro} as well as \textit{in vivo} [21,25,26]. It cannot be ruled out that the responses induced by fenoterol are stronger than those that would have been induced by a partial agonist, but it is unlikely that this would have changed the main conclusions of this study. Furthermore, the cohort we studied was of a relatively limited extent, especially in relation to the low numbers of individuals in some subgroups, particularly genotype II/II, and to the uneven presence of the different genotypes in asthmatic cohorts, as also noticed previously [19]. This implicates that the functional implications of especially genotype II/II need further study either in larger groups of patients or after pre-selection of specific genotypes.

Our genotype analyses contained all the SNPs with a known bearing on gene regulation or receptor expression, thus ignoring the three SNPs downstream from basepair +79. In our opinion this is only of limited impact. The SNPs at +252 and +523 are synonymous and so do not result in amino acid substitution, while the one at + 491 is very uncommon. However it cannot be ruled out completely that these three SNPs have an impact on receptor expression e.g. via an effect on mRNA stability.

Our study confirms that downregulation of \( \beta_2 \)-agonist induced airway responses is more easily substantiated for protection towards a bronchoconstrictive stimulus than for bronchodilation form "baseline", in this case: recovery form methacholine induced bronchoconstriction one hour earlier. This is in line with a recent study showing that susceptibility to bronchodilator tolerance increases when the degree of induced bronchoconstriction increases [27]. The degree of tolerance development was much less for FEV\(_1\) and at the most borderline statistically significant for the cohort as a whole.

With respect to the potential clinical implications of our findings it must be realised that for all genotypes some degree of protection against bronchoconstriction remained after two weeks of \( \beta_2 \)-agonist use. After terbutaline pre-treatment, the differences in the dose response curves between genotypes were attenuated and the maximum difference in improvement in PD\(_{20}\) by the highest dose of fenoterol between the genotypes (II/III versus I/I, figure 1) was 1.5 doubling dose, where differences larger than about one doubling dose are generally considered to be clinically significant, in view of the confidence intervals for repeated determinations of methacholine broncho-provocation thresholds [28]. It is evident that at lower doses of \( \beta_2 \)-agonist, such as normally used by asthmatics in a clinically stable state, the differences are even smaller. Altogether, this implicates that the functional phenotypical differences between the genotypes are probably only of limited clinical significance, at least in stable mild to moderate asthmatics as in our cohort. As we previously argued, such differences are likely to be more relevant in situations with a high state of functional antagonism, such as in asthma exacerbations with severe bronchoconstriction and functionally antagonized receptors by inflammatory mediators, when high doses of short acting \( \beta_2 \)-agonists are used [21].

### Conclusion

Our data and analyses in a cohort of asthmatic patients indicate differences between six distinct \( \beta_2 \)-AR allelic genotypes in the shape of the dose response relationship of a \( \beta_2 \)-AR agonist and in the propensity to develop tolerance for these effects. The genotypes are based upon combinations of three limited allelic haplotypes containing the functionally relevant parts of the \( \beta_2 \)-AR gene. The differences we found are statistically significant and functionally relevant only for bronchoprotection when compared to bronchodilation in terms of recovery from methacholine induced bronchoconstriction, and of a magnitude unlikely to be of clinical significance.

### Competing interests

The department of Pulmonology of the AMC (authors: AV, FRW, HMI, REJ) received an unrestricted research
grant for the conduction of this study and one additional study. There are no competing interests for the other authors.

Authors’ contributions
AV conducted the study, was involved in the analysis of the data and was involved in drafting the manuscript.

EAW aided in the carry out the molecular genetic assays and was involved in drafting the manuscript.

RW carried out the molecular genetic assays
FRW participated in the design of the study
FRGH performed the statistical analysis
HMJ participated in the design of the study and interpretation of the data

RFJ participated in the design of the study and was involved in the analysis of the data and the drafting of the manuscript

Acknowledgements
This study was supported by an unrestricted research grant from Astrazeneca, Zoetemeer, the Netherlands, who also supplied terbutaline and placebo inhalers.

References
1. Green SA, Turki J, Innis M, Liggert SB: Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994, 33:9414-9419.
2. Green SA, Turki J, Bejarano P, Hall IP, Liggert SB: Influence of beta-2 adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 1995, 13:25-33.
3. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R: Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997, 100:3184-3188.
4. Lima JJ, Thomasen DB, Mohamed MH, Eberle LV, Self TH, Johnson JA: Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 1999, 65:519-525.
5. Israel E, Drazen JM, Liggert SB, Boushey HA, Chinchilli RM, Chinchilli VM, Cooper DM, Fahy JV, Fish JE, Ford JD, Kraft M, Kunselman S, Lazarus SC, Lemanske RF, Martin RJ, McLean DE, Peters SP, Silverman EK, Sorkness CA, Szefler SJ, Weiss ST, Yandava CN: The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000, 162:75-80.
6. Israel E, Chinchilli VM, Ford JD, Boushey HA, Chinchilli R, Craig TJ, Dekin A, Fagan JK, Fahy JV, Fish J, Kraft M, Kunselman SJ, Lazarus SC, Lemanske RFJ, Liggert SB, Martin RJ, Mitrza N, Peters SP, Silverman E, Sorkness CA, Szefler SJ, Wechsler ME, Weiss ST, Drazen JM: Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004, 364:1505-1512.
7. Hancox RJ, Sears MR, Taylor DR: Polymorphism of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma. Eur Respir J 1998, 11:589-593.
8. Lipworth B, Koppelman GH, Wheeless AP, Le JJ, Coutie W, Meurs H, Kaufman HF, Postma DS, Hall IP: Beta2 adrenoceptor promoter polymorphisms: extended haplotypes and functional effects in peripheral blood mononuclear cells. Thorax 2002, 57:616-66.
9. Jackson CM, Lipworth B: Benefit-risk assessment of long-acting beta2-agonists in asthma. Drug Saf 2004, 27:243-270.
10. Tan S, Hall IP, Dewar J, Dow E, Lipworth B: Association between beta2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe asthma. Lancet 1997, 350:995-999.
11. Taylor DR, Hancox RJ, McRae W, Cown JG, Flannery EM, MacLachlan CR, Herbisson GP. The influence of polymorphism at position 16 of the beta2-adrenoceptor on the development of tolerance to beta-agonist. J Asthma 2000, 37:691-700.
12. Lipworth BJ, Hall IP, Aaz L, Tan KS, Wheeles A: Beta2-adrenoceptor polymorphism and bronchoprotective sensitivity with regular short- and long-acting beta2-agonist therapy. Clin Sci (Colch.) 1999, 96:253-259.
13. Lee DK, Jackson CM, Bates CE, Lipworth BJ: Cross tolerance to salbutamol and formoterol or salmeterol. Thorax 2004, 59:662-667.
14. Chong LK, Chowdry J, Ghanamani P, Peachell PT: Influence of genetic polymorphisms in the beta2-adrenoceptor on desensitisation in human lung mast cells. Pharmacogenetics 2000, 10:153-162.
15. Moore PE, Laporde JT, Abraham JH, Schwartzman IN, Yandava CN, Silverman ES, Drazen JM, Wand MP, Panettieri RAJ. Shore SA: Polymorphism of the beta(2)-adrenergic receptor gene and desensitization in human airway smooth muscle. Am J Respir Crit Care Med 2000, 162:2117-2124.
16. McGraw DW, Forbes SL, Kramer LA, Liggert SB: Polymorphisms of the 5′ leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J Clin Invest 1998, 102:1927-1932.
17. Parola AL, Kobikla BK: The peptide product of a 5′ leader cistron in the beta 2 adrenergic receptor mRNA inhibits receptor synthesis. J Biol Chem 1994, 269:4497-4505.
18. Scott MG, Swan C, Wheeles AP, Hall IP: Identification of novel polymorphisms within the promoter region of the human beta2 adrenergic receptor gene. Br J Pharmacol 1999, 126:841-844.
19. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Naidabalan, Arnold K, Ruano G, Liggert SB: Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 2000, 97:10483-10488.
20. Westland R, van Aen A, Hansen JH, Jonkers RE. Wierenga EA: Limitation of impact of multiple 5′ single-nucleotide polymorphisms on the transcriptional control of the human beta 2-adrenoceptor gene. Immunogenetics 2004, 56:625-630.
21. van Aen A, Weller FR, Wierenga EA, Hansen JH, Jonkers RE: A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists. Palm Pharmacol Ther 2003, 16:153-161.
22. McGraw DW, Almoosa KF, Paul RJ, Kobilka BK, Liggert SB: Antithetic regulation by beta2-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-adrenergic paradox. J Clin Invest 2003, 112:619-626.
23. Lipworth B, Tan S, Devlin M, Aten K, Baker R, Hendrick D: Effects of treatment with formoterol on bronchoprotection against methacholine. Am J Med 2004, 116:431-438.
24. Scola AM, Chong LK, Chess-Williams R, Peachell PT: Influence of agonist intrinsic activity on the desensitisation of beta2-adrenoceptor-mediated responses in mast cells. Br J Pharmacol 2004, 143:71-80.
25. Molimard M, Naline E, Zhang Y, Le GV, Begaud B, Advenier C: Long- and short-acting beta2 adrenergic agonist interactions in human contracted bronchi. Eur Respir J 1998, 11:583-588.
26. Palmqvist M, Ibsen T, Mellen A, Lotvall J: The influence of polymorphism at position 16 of the beta2-adrenoceptor on the development of tolerance to beta-agonist. J Asthma 2000, 37:691-700.
27. Wraight JM, Hancox RJ, Herbisson GP, Cowan JC, Flannery EM, Taylor DR: Bronchodilator tolerance: the impact of increasing bronchoconstriction. Eur Respir J 2003, 21:810-815.
28. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, MacIntyre NR, McKay RT, Wanger J, Anderson SD, Cockcroft DW, Fisher JE, Sterk PJ: Guidelines for methacholine and exercise bronchoprovocation testing in adults. Eur Respir J 2005, 26:776-831.
challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000, 161:309-329.